Issue 9/2012

  • Is gene therapy finally coming into its own?

    In this issue:


    Is gene therapy finally coming into its own?

    After a balancing act that went down to the wire with regulators – and left its predecessor company bankrupt – uniQure biotherapies now looks set to become the first pharma company to gain approval for a gene therapy in Europe. the concept of ‘curing’ rare inherited diseases by altering a patient’s genome in key cells has been around for decades. But disastrous, highly-publicised failures to harness the technology in the past frightened off developers and patients alike. Now that looks set to change.

Volume 2014

Volume 2013

Volume 2012

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/9/pos/1.html?sort=desc&cHash=8305edff5982cb307c5ea48106acb36a

Kurszettel

Alle Kurse

TOP

  • CYTOS0.32 CHF14.29%
  • SANTHERA92.00 CHF5.75%
  • SARTORIUS106.00 EUR4.07%

FLOP

  • THERAMETRICS0.06 CHF-14.29%
  • EPIGENOMICS5.07 EUR-7.31%
  • 4SC0.85 EUR-6.59%

TOP

  • ADDEX3.56 CHF52.8%
  • CYTOS0.32 CHF45.5%
  • BB BIOTECH244.00 EUR23.3%

FLOP

  • ACTELION96.95 CHF-18.3%
  • THERAMETRICS0.06 CHF-14.3%
  • MAGFORCE4.65 EUR-13.2%

TOP

  • SANTHERA92.00 CHF2217.4%
  • BB BIOTECH244.00 EUR102.2%
  • CO.DON2.30 EUR60.8%

FLOP

  • CYTOS0.32 CHF-90.2%
  • MOLOGEN5.82 EUR-49.8%
  • 4SC0.85 EUR-47.2%

No liability assumed, Date: 26.01.2015